Evidence map›Paper›PMID 34991725›Full record

ArticleMicrobiome2022

Host tp53 mutation induces gut dysbiosis eliciting inflammation through disturbed sialic acid metabolism.

Jae-Geun Lee, Soohyun Lee, Juhee Jeon, Hyun Gi Kong, Hyun-Ju Cho, Jong-Hwan Kim, Seon-Young Kim, Myung Jin Oh, Daum Lee, Nari Seo and 5 more

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Microbiome, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Atypical El TorMicrobiology spectrum · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Clonal hematopoiesis and bone marrow inflammation.Translational research : the journal of laboratory and clinical medicine · 2023
    Review
  15. Article
  16. Application of zebrafish in the study of the gut microbiome.Animal models and experimental medicine · 2022
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Jae-Geun Lee *Disease Target Structure Research Center, KRIBB, Daejeon, 34141, Republic of Korea.
Soohyun Lee *Infectious Disease Research Center, KRIBB, Daejeon, 34141, Republic of Korea.
Juhee Jeon *Disease Target Structure Research Center, KRIBB, Daejeon, 34141, Republic of Korea.
Hyun Gi KongInfectious Disease Research Center, KRIBB, Daejeon, 34141, Republic of Korea.
Hyun-Ju ChoDisease Target Structure Research Center, KRIBB, Daejeon, 34141, Republic of Korea.
Jong-Hwan KimKorean Bioinformation Center, KRIBB, Daejeon, 34141, Republic of Korea.
Seon-Young KimKRIBB School, University of Science and Technology, 217 Gajeong-ro, Yuseong-gu, Daejeon, 34113, Republic of Korea.
Myung Jin OhGraduate School of Analytical Science and Technology, Chungnam National University, Daejeon, 34134, Republic of Korea.
Daum LeeGraduate School of Analytical Science and Technology, Chungnam National University, Daejeon, 34134, Republic of Korea.
Nari SeoGraduate School of Analytical Science and Technology, Chungnam National University, Daejeon, 34134, Republic of Korea.
Ki Hun ParkDivision of Applied Life Science (BK21 plus), IALS, Gyeongsang National University, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea.
Kweon YuDisease Target Structure Research Center, KRIBB, Daejeon, 34141, Republic of Korea.
Hyun Joo AnGraduate School of Analytical Science and Technology, Chungnam National University, Daejeon, 34134, Republic of Korea.
Choong-Min RyuKRIBB School, University of Science and Technology, 217 Gajeong-ro, Yuseong-gu, Daejeon, 34113, Republic of Korea. cmryu@kribb.re.kr.ORCID 0000-0002-7276-1189
Jeong-Soo Lee *Disease Target Structure Research Center, KRIBB, Daejeon, 34141, Republic of Korea. jeongsoo@kribb.re.kr.ORCID 0000-0002-8491-4429
Chungnam National University · KRKorean Register (South Korea) · KRConvergence Research Center for Diagnosis Treatment and Care System of Dementia · KRKorea Research Institute of Bioscience and Biotechnology · KRGyeongsang National University · KRKorea Center for Disease Control and Prevention · KRRural Development Administration · KRSoonchunhyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHost tp53 mutations are frequently found during the early stages of colitis-associated colorectal cancer (CAC), but whether such mutations induce gut microbiota dysbiosis and chronic intestinal inflammation that contributes to the development of CAC, remains unknown.

resultsWe found that zebrafish tp53 mutant larvae exhibited elevated intestinal inflammation, by monitoring the NFκB activity in the mid-distal intestines of zebrafish larvae using an NFκB:EGFP transgenic reporter line in vivo as well as neutrophil infiltration into the intestine. This inflammation was due to dysbiotic gut microbiota with reduced diversity, revealed using both 16S rRNA amplicon sequencing and a germfree larva model. In this dysbiosis, Aeromonas spp. were aberrantly enriched as major pathobionts and exhibited the capacity for aggressive colonization in tp53 mutants. Importantly, the ex-germfree experiments supported the causality of the host tp53 mutation for inducing the inflammation. Transcriptome and high-performance liquid chromatography analyses of the host gastrointestinal tracts identified dysregulated sialic acid (SA) metabolism concomitant with increased host Neu5Gc levels as the key determinant of aberrant inflammation, which was reversed by the sialidase inhibitors oseltamivir and Philippin A.

conclusionsThese results demonstrate a crucial role for host tp53 in maintaining symbiosis and immune homeostasis via SA metabolism. Disturbed SA metabolism via a tp53 mutation may be exploited by specific elements of the gut microbiome, eliciting both dysbiosis and inflammation. Manipulating sialometabolism may therefore provide an efficacious therapeutic strategy for tp53 mutation-induced dysbiosis, inflammation, and ultimately, related cancers. Video Abstract.

Indexed as

DysbiosisN-Acetylneuraminic AcidAnimalsInflammationMutationRNA, Ribosomal, 16SZebrafishN-Acetylneuraminic AcidRNA, Ribosomal, 16SDysbiosisGermfreeHostInflammationLarval intestineMicrobiotaSialidase inhibitionSialometabolismtp53 mutationZebrafish

Identifiers

PMID34991725
PMCPMC8733924
OpenAlexW4206518470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.